- Previous
- Next
Medicines appraisal cards have been developed for the Guidelines audience to announce new recommendations from the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Medicines Strategy Group (AWMSG).
Tofacitinib▼ (Xeljanz®) SMC2122, SMC1298/18, SMC2116
Information intended for healthcare professionals only.
Tofacitinib▼ (Xeljanz®) NICE TA547, TA480, TA543
Information intended for healthcare professionals only.
AWMSG card: Semaglutide 0.25 mg, 0.5 mg and 1 mg solution for injection in pre-filled pen (Ozempic®▼)
Funded by Novo Nordisk Limited
Semaglutide 0.25 mg, 0.5 mg and 1 mg solution for injection in pre-filled pen (Ozempic®▼) SMC No. (2092)
Funded by Novo Nordisk Limited
Guidelines supplements are written by experts and typically discuss a piece of national guidance, pulling out key learning points for GPs.
Supporting smoking cessation in patients with COPD is the most effective intervention
A comparison of once-daily triple therapy with once-daily dual therapy in the treatment of symptomatic COPD—the IMPACT trial
Recognising and managing adult ADHD in primary care
The role of morphine in the management of cancer pain
Type 2 diabetes: an overview of the SIGN guideline on pharmacological management of glycaemic control